A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

BACKGROUND: The phosphate ester PR-104 is rapidly converted in vivo to the alcohol PR-104A, a nitrogen mustard prodrug that is metabolised to hydroxylamine (PR-104H) and amine (PR-104M) DNA crosslinking agents by one-electron reductases in hypoxic cells and by aldo-keto reductase 1C3 independently o...

Descripción completa

Detalles Bibliográficos
Autores principales: McKeage, Mark J, Gu, Yongchuan, Wilson, William R, Hill, Andrew, Amies, Karen, Melink, Teresa J, Jameson, Michael B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205073/
https://www.ncbi.nlm.nih.gov/pubmed/21982454
http://dx.doi.org/10.1186/1471-2407-11-432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205073/
https://www.ncbi.nlm.nih.gov/pubmed/21982454
http://dx.doi.org/10.1186/1471-2407-11-432

Ejemplares similares